Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Anticipated Size Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Over The Five-Year Period 2025–2029?
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market has experienced rapid expansion in recent years. It is forecast to grow from $1.98 billion in 2024 to $2.19 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.8%. Historically, this market’s development was influenced by the emergence of antibiotic resistance, various awareness campaigns and educational initiatives, and changes in policy.
The market for chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing is projected to undergo rapid expansion over the next few years. It is expected to reach $3.22 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.1%. This anticipated growth during the forecast period can be attributed to factors such as telemedicine and telehealth, customized medicine approaches, the proliferation of point-of-care testing, and population health management strategies. Noteworthy trends in the upcoming period involve the increased adoption of rapid point-of-care testing, individualized testing methods, integrated multi-disease testing platforms, and community-centric testing and outreach programs.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp
What Are The Top Growth Drivers Impacting The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Outlook?
The rising prevalence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the future. STIs are conditions resulting from infections by bacteria, viruses, or parasites, which spread through sexual activity. The increase in STI rates can be attributed to factors such as insufficient comprehensive sex education, heightened sexual activity, associated stigma, and various access barriers. These tests, specifically for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), play a crucial role in identifying and managing STIs through prompt diagnosis, subsequent treatment, and the prevention of further spread. A prime example is the data from July 2023, where reports from the World Health Organization (WHO) in Switzerland, an intergovernmental entity, indicated that globally over 1 million STIs are contracted daily, and approximately 374 million new infections of 1 of 4 treatable STIs occur annually. This sustained increase in sexually transmitted infections thus serves as a primary impetus for the growth of the CTNG testing market.
What Are The Emerging Segments Gaining Attention In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testingmarket covered in this report is segmented –
1) By Test Type: Laboratory; Point Of Care Testing
2) By Product: Assays And Kits; Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology; Polymerase Chain Reaction; Immunodiagnostics; Other Technologies
4) By End User: Diagnostic Laboratories; Hospitals And Clinics; Other End Users
Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT); Polymerase Chain Reaction (PCR) Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Immunofluorescence Assay (IFA); Culture Tests; Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT); Lateral Flow Assays; Immunochromatographic Tests; Self-Testing Kits; Loop-Mediated Isothermal Amplification (LAMP); Microfluidics-Based Tests
What Trends Are Expected To Drive The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Major companies in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are prioritizing the creation of innovative testing solutions, exemplified by systems like the BD COR MX/PX System. This advanced molecular diagnostic platform for infectious diseases is designed to fulfill the need for accurate, efficient, and scalable diagnostic approaches to combat the rising prevalence of sexually transmitted infections. The BD COR MX/PX System represents a sophisticated laboratory apparatus or system engineered to quickly and effectively process numerous samples for the presence of infectious agents. For example, in May 2022, Becton Dickinson and Company, a medical device company based in the US, introduced its new, fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX/PX System. This system is developed to streamline operations in large laboratories that manage extensive volumes of infectious disease tests, encompassing those for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing. It automates the complete workflow, from sample intake to result provision, through the use of robotics and software algorithms. This capability can substantially enhance operational efficiency and potentially decrease the waiting periods for test results. Additionally, its features include automation, high-throughput capacity, dual DNA targets, and a modular, scalable design.
Who Are The Major Companies Operating In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech
Download The Full Report For Exclusive Market Findings:
Which Global Regions Are Influencing The Competitive Landscape Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=14667&type=smp
Browse Through More Reports Similar to the Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market 2025, By The Business Research Company
Iot Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/iot-testing-global-market-report
Poc Hba1C Testing Market 2025
https://www.thebusinessresearchcompany.com/report/poc-hba1c-testing-market
Veterinary Laboratory Testing Services Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model